{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:36:17Z","timestamp":1794274577749,"version":"4.9.0"},"reference-count":26,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["n\/a - the survey was sponsored by GSK"],"award-info":[{"award-number":["n\/a - the survey was sponsored by GSK"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,7,30]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD)-associated anaemia has substantial biopsychosocial impacts. This study explores the impact of CKD-associated anaemia and treatment preferences from the patient perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Anonymised online survey implemented by Ipsos UK on behalf of the National Kidney Federation and GSK from October 2022 to January 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Data were collected from UK adults living with CKD (self-reported).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Outcome measures were exploratory and not predefined. The cross-sectional survey was designed to explore the biopsychosocial impact of living with anaemia on individuals with CKD; their unmet needs; the treatment strategies typically implemented and the associated barriers\/facilitators to adherence; the healthcare professional\u2013patient relationship with regard to anaemia diagnosis and management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 101 participants, 90 (89%) were patients with CKD and 11 (11%) were informal carers. 96 (95%) participants reported symptom(s) relevant to their experience of CKD. 88 (87%) participants reported symptom(s) associated with anaemia and 61 (64%) expressed an impact on daily life including 18 (19%) unable to perform daily activities, 13 (14%) unable to go to work and 9 (9%) reporting poor social life\/interactions. 85 (84%) participants reported they have received treatment for anaemia: intravenous iron (n=55, 54%), iron tablets (n=29, 29%), erythropoietin-stimulating agents (ESAs) via an autoinjector (n=28, 28%), ESA injections via a syringe (n=24, 24%), ESA injections via a dialysis machine (n=17, 17%), folic acid (n=22, 22%) and blood transfusion (n=17, 17%). Six of seven (86%) participants who received their ESA from a healthcare professional at home preferred injections whereas 13\/27 (48%) participants who injected themselves at home preferred oral tablets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is not a \u2018one-size-fits-all\u2019 approach to the management of CKD-associated anaemia. A personalised approach incorporating the treatment preferences of the individual should be explored when discussing treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-087802","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T06:13:59Z","timestamp":1723875239000},"page":"e087802","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["UK survey of patient and caregiver perspectives on the impact of chronic kidney disease-associated anaemia"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-5408","authenticated-orcid":false,"given":"Katherine L","family":"Hull","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, UK"},{"name":"John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemma","family":"Reast","sequence":"additional","affiliation":[{"name":"Ipsos, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Clair","sequence":"additional","affiliation":[{"name":"GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Kent","sequence":"additional","affiliation":[{"name":"GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Moore","sequence":"additional","affiliation":[{"name":"GSK, Brentford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Pittaway","sequence":"additional","affiliation":[{"name":"Ipsos, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Revell","sequence":"additional","affiliation":[{"name":"National Kidney Federation, Worksop, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, Leicester, UK"},{"name":"John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"2025121511230731000_14.8.e087802.1","unstructured":"Kidney Research UK . Kidney disease: a UK public health emergency, Available: https:\/\/www.kidneyresearchuk.org\/about-us\/influencing-change\/health-economics-report\/"},{"key":"2025121511230731000_14.8.e087802.2","unstructured":"UK Renal Registry . UK Renal Registry 25th Annual Report \u2013 data to 31\/12\/2021, Available: https:\/\/ukkidney.org\/audit-research\/annual-report"},{"key":"2025121511230731000_14.8.e087802.3","unstructured":"European Medical Journal . Anaemia of chronic kidney disease: aligning patient and physician awareness \u2013 interviews with three key opinion leaders and patient advocates, Available: https:\/\/www.emjreviews.com\/nephrology\/article\/anaemia-of-chronic-kidney-disease-aligning-patient-and-physician-awareness-interviews-with-three-key-opinion-leaders-and-patient-advocates\/"},{"key":"2025121511230731000_14.8.e087802.4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13696998.2019.1588738","article-title":"Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review","volume":"22","author":"Spinowitz","year":"2019","journal-title":"J Med Econ"},{"key":"2025121511230731000_14.8.e087802.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-01746-4","article-title":"Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data","volume":"21","author":"van Haalen","year":"2020","journal-title":"BMC Nephrol"},{"key":"2025121511230731000_14.8.e087802.6","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7692376","article-title":"The Impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-a systematic literature review","volume":"2020","author":"Palaka","year":"2020","journal-title":"Int J Nephrol"},{"key":"2025121511230731000_14.8.e087802.7","unstructured":"Macdougall IC , Kai-Uwe E . Anaemia in chronic kidney disease. In: Feehally J , Floege J , Tonelli M , et al ., eds. Comprehensive clinical nephrology. Elsevier, 2019: 958\u201366."},{"key":"2025121511230731000_14.8.e087802.8","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.37"},{"key":"2025121511230731000_14.8.e087802.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6724.573"},{"key":"2025121511230731000_14.8.e087802.10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01498","article-title":"Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective","volume":"9","author":"Aapro","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025121511230731000_14.8.e087802.11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02730608"},{"key":"2025121511230731000_14.8.e087802.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-180334","article-title":"Addressing chronic anemia in sickle cell disease: characterizing Erythropoiesis-Stimulating Agent (ESA) utilization and practice patterns among providers","volume":"142","author":"Kovalenko","year":"2023","journal-title":"Blood"},{"key":"2025121511230731000_14.8.e087802.13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12968\/jorn.2012.4.2.81","article-title":"Anaemia management in chronic kidney disease patients","volume":"4","author":"Pagels","year":"2012","journal-title":"J Renal Nurs"},{"key":"2025121511230731000_14.8.e087802.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.12.011"},{"key":"2025121511230731000_14.8.e087802.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2020.12.002"},{"key":"2025121511230731000_14.8.e087802.16","unstructured":"Digital Science . Dimensions [software]. n.d. Available: https:\/\/app.dimensions.ai"},{"key":"2025121511230731000_14.8.e087802.17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ackd.2019.04.003","article-title":"The impact of anemia treatment on health-related quality of life in patients with chronic kidney disease in the contemporary era","volume":"26","author":"Finkelstein","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2025121511230731000_14.8.e087802.18","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.34925"},{"key":"2025121511230731000_14.8.e087802.19","first-page":"90","article-title":"Compliance with subcutaneous erythropoietin in peritoneal dialysis patients","volume":"16","author":"Nicoletta","year":"2000","journal-title":"Adv Perit Dial"},{"key":"2025121511230731000_14.8.e087802.20","doi-asserted-by":"crossref","DOI":"10.1177\/23743735221092629","article-title":"Understanding patient perspectives of the impact of anemia in chronic kidney disease: a United States patient survey","volume":"9","author":"Grandy","year":"2022","journal-title":"J Patient Exp"},{"key":"2025121511230731000_14.8.e087802.21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IJNRD.S291393","article-title":"Understanding patient perspectives and awareness of the impact and treatment of anemia with chronic kidney disease: a patient survey in China","volume":"14","author":"Hao","year":"2021","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2025121511230731000_14.8.e087802.22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12325-022-02367-z","article-title":"Preferences for anaemia treatment attributes among patients with non-dialysis-dependent chronic kidney disease","volume":"40","author":"Alexandre","year":"2023","journal-title":"Adv Ther"},{"key":"2025121511230731000_14.8.e087802.23","doi-asserted-by":"crossref","unstructured":"Alexandre AF , Morga A , Marsh K , et al . P0865A Qualitative study of patients\u2019 preference for the treatment of anaemia associated with chronic kidney disease. Nephrol Dial Transplant 2020;35. doi:10.1093\/ndt\/gfaa142.P0865","DOI":"10.1093\/ndt\/gfaa142.P0865"},{"key":"2025121511230731000_14.8.e087802.24","doi-asserted-by":"crossref","unstructured":"Lu E , Okoro T , Heidenreich S , et al . MO528: identifying drivers of patients\u2019 and physicians\u2019 preferences for treatments of anemia of chronic kidney disease: a qualitative study. Nephrol Dial Transplant 2022;37. doi:10.1093\/ndt\/gfac072.010","DOI":"10.1093\/ndt\/gfac072.010"},{"key":"2025121511230731000_14.8.e087802.25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01524-6"},{"key":"2025121511230731000_14.8.e087802.26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000502208","article-title":"Patient-centred outcomes in anaemia and renal disease: a systematic review","volume":"6","author":"Staibano","year":"2020","journal-title":"Kidney Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-087802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:23:15Z","timestamp":1765826595000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-087802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,17]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/bmjopen-2024-087802"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087802","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087802.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-087802.supp2","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}